Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2021 Mar;61(3):830-838.
doi: 10.1111/trf.16208. Epub 2020 Dec 14.

A retrospective study assessing the characteristics of COVID-19 convalescent plasma donors and donations

Affiliations

A retrospective study assessing the characteristics of COVID-19 convalescent plasma donors and donations

Claudia Del Fante et al. Transfusion. 2021 Mar.

Abstract

Background: Although many trials are currently investigating the safety and efficacy of convalescent plasma (CP) in critically ill COVID-19 patients, there is a paucity of ongoing and published studies evaluating the CP donors' side. This retrospective study reports the first Italian experience on CP donors' selection and donations.

Methods: Patients aged 18-68 years who had recovered from COVID-19 at least 2 weeks previously were recruited between March 18 and June 30, 2020 in a study protocol at the Italian hospitals of Pavia and Mantova.

Results: During the study period, 494 of 512 donors recruited were judged eligible and underwent 504 plasmapheresis procedures. Eighty-five percent (437/512) of the CP donors were males. The average time between symptom recovery and CP donation was 36.6 (±20.0) days. Four hundred and eighty-eight plasmapheresis procedures (96.8%) were concluded and each unit was divided into two subunits (total 976) with an average volume of 316.2 (±22.7) mL. Ninety-three percent (460/494) of CP donors at the time of plasma donation had a neutralizing IgG titer ≥1:80. Plasmapheresis-related adverse reactions occurred in 2.6% (13/504) of cases; all the reactions were mild and none required therapeutic intervention. Donors' age and COVID-19 severity were positively associated with greater antibody responses.

Conclusion: This study demonstrates the feasibility and safety of a pilot CP program conducted in Italy. The identification of factors (ie, age and severity of COVID-19) positively associated with higher neutralizing antibody titers at the time of donation may help to optimize the selection of CP donors.

PubMed Disclaimer

Conflict of interest statement

The authors have disclosed no conflicts of interest.

Figures

FIGURE 1
FIGURE 1
Correlation (A) and partial correlation matrices (B) illustrated by weighted network visualization. The nodes are the variables, and the connectors (“arcs” or “edges”) are the pairwise correlations. Green color indicates positive correlations, red color indicates negative correlations, and numbers express the value of the correlations. Non‐significant arcs were omitted [Color figure can be viewed at wileyonlinelibrary.com]
FIGURE 2
FIGURE 2
Proposed causal interpretation of correlation between variables. The directed arcs (arrows) indicate causal effects. The undirected edge marks an unresolved correlation (possibly joint dependence on an unknown variable)
FIGURE 3
FIGURE 3
Predictive effect of age (agecat) on neutralizing antibody titer (l2tit) [Color figure can be viewed at wileyonlinelibrary.com]
FIGURE 4
FIGURE 4
Predictive effect of clinical severity of the disease on neutralizing antibody titer (l2tit) [Color figure can be viewed at wileyonlinelibrary.com]
FIGURE 5
FIGURE 5
Logistic regression on the predictive effect of age on probability of clinical severity. The lower levels, 1 and 2, decline with advancing age, whereas the opposite appears with the higher levels [Color figure can be viewed at wileyonlinelibrary.com]

References

    1. WHO . Coronavirus disease (COVID‐2019). Situation reports August 2020. Available from: https://www.who.int/docs/default-source/coronaviruse/situation-reports/2.... Accessed August 7, 2020.
    1. Perotti C, Baldanti F, Bruno R, et al. Mortality reduction in 46 patients with severe COVID‐19 treated with hyperimmune plasma. A proof‐of‐concept, single‐arm, multicenter trial. Haematologica. 2020. 10.3324/haematol.2020.261784. - DOI - PMC - PubMed
    1. Shen C, Wang Z, Zhao F, et al. Treatment of 5 critically ill patients with COVID‐19 with convalescent plasma. JAMA. 2020;323:1582–1589. - PMC - PubMed
    1. Duan K, Liu B, Li C, et al. Effectiveness of convalescent plasma therapy in severe COVID‐19 patients. Proc Natl Acad Sci USA. 2020;117:9490–9496. - PMC - PubMed
    1. Zeng QL, Yu ZJ, Gou JJ, et al. Effect of convalescent plasma therapy on viral shedding and survival in COVID‐19 patients. J Infect Dis. 2020;222:38–43. - PMC - PubMed

Publication types

MeSH terms